TY  - GEN
AU  - Cebrian, Arancha
AU  - Gomez del Pulgar, Teresa
AU  - Jose Mendez-Vidal, Maria
AU  - Luisa Gonzalvez, Maria
AU  - Lainez, Nuria
AU  - Castellano, Daniel
AU  - Garcia-Carbonero, Iciar
AU  - Esteban, Emilio
AU  - Isabel Saez, Maria
AU  - Villatoro, Rosa
AU  - Suarez, Cristina
AU  - Carrato, Alfredo
AU  - Munarriz-Ferrandiz, Javier
AU  - Basterrechea, Laura
AU  - Garcia-Alonso, Mirta
AU  - Luis Gonzalez-Larriba, Jose
AU  - Perez-Valderrama, Begona
AU  - Cruz-Jurado, Josefina
AU  - Gonzalez del Alba, Aranzazu
AU  - Moreno, Fernando
AU  - Reynes, Gaspar
AU  - Rodriguez-Remirez, Maria
AU  - Boni, Valentina
AU  - Mahillo-Fernandez, Ignacio
AU  - Martin, Yolanda
AU  - Viqueira, Andrea
AU  - Garcia-Foncillas, Jesus
PY  - 2017
DO  - 10.1038/srep41371
SN  - 2045-2322
UR  - http://hdl.handle.net/20.500.12105/20405
AB  - Sunitinib is the currently standard treatment for metastatic renal cell carcinoma (mRCC). Multiple candidate predictive biomarkers for sunitinib response have been evaluated but none of them has been implemented in the clinic yet. The aim of this...
LA  - eng
PB  - Nature Publishing Group
KW  - Disease-Free Survival
TI  - Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
TY  - research article
ER  -